Pfizer Corporation

Chiral Technologies Europe

George Joseph Quallich

Lewin Theophilus Wint

Peter Robert Rose

Evgenyi Y Shalaev

George Chang

Antone John deBettencourt, Iii

Charles W Murtiashaw

Michael J Castaldi

Michael T Williams

Carl B Ziegler, Jr

Robert Wayne Dugger

Frank R Busch

Jeffrey W Raggon

John Anthony Ragan

Stephen S Massett

Subramanian Sam Guhan

Carl Bernard Ziegler

Douglas John Meldrum Allen

Robert C Friedmann

Paul D Hill

Shane Allen Eisenbeis

David Jon Am Ende

Robert Mark Guinn

Peter H Dorff

Alyson Kay Conrad

Gregory Randall Young

Pamela Jane Clifford

Teresa Woodall Makowski

Oliver Dapremont

Fiona Geiser

Tong Zhang

A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.

Process for forming amorphous atorvastatin

The present invention is directed to certain pharmaceutically acceptable salts of the therapeutically potent selective serotonin reuptake inhibitor, sertraline: and pharmaceutical compositions thereof, wherein said salts are selected from the group consisting of the p-toluenesulfonic acid salt, the fumaric acid salt, the benzenesulfonic acid salt, the benzoic acid salt, the L-tartaric acid salt and the (&#x2212;)-camphor-10-sulfonic acid salt.

Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof

A process for preparing an anhydrous benzoate salt in crystalline form having the formula I:and the corresponding benzoate monohydrate in crystalline form. The benzoate salts and pharmaceutical compositions thereof are selective kappa-receptor agonists, and are useful as analgesics, anesthetics, anti-inflammatory or neuroprotective agents, or in the treatment of arthritis, stroke or functional bowel disease.

Crystalline anhydrous and monohydrate benzoate salts of (2'S,3S)-3-hydroxy-N-(2-[N-methyl-N-4-(N-propylamino-carbonyl)phenyl]amino-2-phenyl)-ethylpyrrolidine

Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof

Succinic acid salts of 5,7,14-triazatetracyclo&lsqb;10.3.1.02,11.04,9&rsqb; -hexadeca-1(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

A process for the production of enantiomerically pure or optically enriched sertraline-tetralone from a mixture containing two enantiomers using continuous chuomatography. The chromatography comprises a liquid mobile phase comprising at least one polar solvent and a solid chiral stationary phase comprising a derivatized polysaccharide that is selected from amylosic, cellulosic, chitosan, xylan, curdlan, and inulan class of polysaccharide.

Process for the production of enantiomerically pure or optically enriched sertraline-tetralone using continuous chromatography

Two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo&lsqb;2.2.2&rsqb;oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate monohydrate (the monohydrates) are Form A and Form B. The pharmaceutical composition containing at least one of these polymorphs has advantageous stability for formulation to treat acute emesis in patient receiving chemotherapy. The administration of this pharmaceutical composition is conventional oral by preferably tablet or capsule and intravenous. A method of making A and B Forms is also disclosed.

Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions

Process for preparing cyclic thioamides

A method for preparing pyrrole-carboxyamides which selectively bind to GABAa receptors; which comprises reacting 1,3-cycloakane-diones with bromoethylacetate followed by reaction of the resulting product with an acid halide followed by reaction with an aromatic amine and finally with an amonium source at an elevated temperature.

Method of synthesis of pyrrole amides

A single crystalline polymorphic form (2S,3S)-N-(methoxy-5-t-butylphenylmethyl-2-diphenylmethyl-1-azobicyclo&lsqb;2,2,2&rsqb; octan-3-amine citrate(citrate monohydrate) and its pharmaceutical composition. The pharmaceutical composition of the polymorphic form if the citrate monohydrate has advantageous stability for formulation to treat emesis. The administration of this pharmaceutical composition is immediate release, oral dosage form preferably by tablet or capsule or intravenous.

Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions

Apo B-secretion/MTP inhibitory amides

The anantoselective borane reduction of prochiral ketones to optically pure alcohols is effectively achieved by performing the reduction in the precence of catalytic amounts of the new and valuable oxazaborolidine compounds of formulas (I) and (II). The compounds of formulas (I) and (II) may be isolated and purified prior to use in the reduction reactions or the compounds of formulas (I) and (II) may be generated in situ. ##STR1##

Enantioselective oxazaborolidine catalysts

The enantioselective borane reduction of prochiral ketones to optically pure alcohols is effectively achieved by performing the reduction in the presence of catalytic amounts of the new and valuable oxazaborolidine compounds of formulae (I) and (II). The compounds of formulae (I) and (II) may be isolated and purified prior to use in the reduction reactions or the compounds of formulae (I) and (II) may be generated in situ.

Growing community of inventors

North Stonington, CT, United States of America

George Joseph Quallich